TACE is standard of care in the BCLC guidelines for HCC, and we recognise that there is still scope for improvement, for example complete response rates, duration of response, leading to the need for retreatment.
As Terumo we are proud that we have generated in recent years a large set of clinical data leading to a new concept of advanced TACE. Several recent clinical publications using the Terumo portfolio have shown new evidence to further improve TACE.
This evidence could further strengthen the case for TACE at the oncological tumour board.
The latest clinical evidence with the Terumo portfolio in DEM-TACE and Occlusafe-TACE brings new perspectives on the future of TACE treatment:
Our ultimate goal by taking TACE to the next level: to Prolong HCC patients Life expectancy
Improving complete response rates and maintaining this response lead to an increase in overall survival1
DEM-TACE treatments reach high complete response rates:1
60% Complete response rate leading to almost 3 years overall survival (35.8month) (n=586 patients)1
Even when multiple treatments are required for larger , complex tumours2
20% of patients achieved complete response after 3rd or 4th TACE procedures (n=97)2
De Baere T et al. Presented at ESMO GI 2020 (pooled analyses)
de Baere T et al. Cancers (Basel) 2020;12:E3405 (PARIS registry)
Watch the videos below - which are of presentations from ECIO 2021.
Discover our clinical evidence and case studies concerning this topic.
Giammaria Fiorentini, Donatella Sarti, Riccardo Carandina, Luca Mulazzani, Cinzia Mincarelli, Roberto Candelari, Renato Argirò, Caterina Fiorentini & Camillo Aliberti
Featured product: LifePearl® Drug Elutable Microspheres
Featured products: LifePearl® Drug Elutable Microspheres, Occlusafe® Temporary Occlusion Balloon Catheter
Gontran Verset et al. Hepatic Oncology(2020)
Featured product: Occlusafe® Temporary Occlusion Balloon Catheter
Pierleone Lucatelli et al. CVIR(2019)
Rita Golfieri et al. CVIR(2021)
T De Baere et al Annals of oncology
(2020) VOLUME 31, SUPPLEMENT 3, S220, JULY 01
Philippe L. Pereira et al Cardiovasc Intervent
Radiol (2020) https://doi.org/10.1007/s00270-020-02646-8
Featured products: Occlusafe® Temporary Occlusion Balloon Catheter, LifePearl® Drug Elutable Microspheres
Pierleone Lucatelli et al J Vasc Interv Radiol (2019):1–9 DOI: https://doi.org/10.1016/j.jvir.2018.10.026
Giammaria Fiorentini et al World J Gastrointest Oncol (2017); 9(9): 379-384 DOI: 10.4251/wjgo.v9.i9.379
Giammaria Fiorentini et al in vivo (2020) 34: 683-686 DOI:10.21873/invivo.11824
Geert Maleux et al Anti-Cancer Drugs (2020) Nov; 31(10):1084-1090. doi:10.1097/CAD.0000000000000980.
T De Baere et al. Cancers (2020), 12, 3405; doi:10.3390/cancers12113405
Filipe Veloso Gomes et al, J Vasc Interv Radiol (2018):1–9 DOI: https://doi.org/10.1016/j.jvir.2018.02.004
Masahiro Ogawa, Kentaro Takayasu, Midori Hirayama, Takao Miura, Katsuhiko Shiozawa, Masahisa Abe, Naoki
Matsumoto, Hiroshi Nakagawara, Shu Ohshiro, Toshiki Yamamoto, Naohide Tanaka, Mitsuhiko Moriyama, Haruomi Mutou, Yoshinobu Yamamoto and Toshiyuki Irie
Our sales representatives are here for you.
Thank you for contacting us!
We typically respond within 2 business days and will come back to you as soon as possible.
This webpage can include promotional content regarding one or several products of Terumo Europe, or some procedures concerning the use or implantation of such products. This webpage is exclusively intended for healthcare professionals and is in no event directed to the general public
For Pharmaceutical Professionals interested in our B2B products portfolio, please visit Terumo Pharmaceutical Solutions.
This is HCP only content
website and cannot be refused. Other cookies are only placed if you choose to do so. For further information, please read our cookies policy.
Essential cookies to ensure the website functions well.
Cookies to help us measure the general use of our website.
Cookies that save personal information while browsing.